Tenet Healthcare Corporation (THC) is a publicly traded company in the Healthcare — Medical - Care Facilities industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Tenet Healthcare Corporation operates as a broad-ranging provider of health solutions. The company organizes its operations across three main divisions: Hospital Operations and Other, Ambulatory Care, and Conifer. Within its network of acute care facilities, Tenet delivers a full spectrum of essential services. These include core hospital functions such as operating and recovery suites, radiology and respiratory therapy, clinical laboratories, and on-site pharmacies.
Is Tenet Healthcare Corporation stock overvalued or undervalued in 2026?
Tenet Healthcare Corporation (THC) trades at 10.4× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $789 (+194 %). Note: these prices use the last twelve months' earnings, and analysts expect them to fall 19 % in 2027; at this price, its 2027 P/E would be 12.7×.
Kaplio overview: Tenet Healthcare Corporation
Market cap $22B · 52 weeks $161 – $281 (4 % below the high) · P/E 10.4× · 2027 expected P/E 12.7× · Dividend none · Next earnings October 29, 2026 · expected EPS $4.68 · Closing price, Oct 28 · accounts published Jul 23.
- Valuation: P/E 10.4× (cheap).
- Business: ROIC 12 % (fair).
- Balance sheet: Net debt/EBITDA 2.3× (passes, near the threshold).
- Earnings: 8 of 8 (uneven).
Analysts expect earnings per share to fall 19 % in 2027: at this price, its 2027 P/E would be 12.7×.
What would it be worth at its usual multiples?
At its sector median (30.4×) $789 (+194 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Note: these prices use the last twelve months' earnings, and analysts expect them to fall 19 % in 2027; at this price, its 2027 P/E would be 12.7×.
What matters in pharma: 5 of 7 pass
- R&D / Revenue 0.0 %, fails.
- ROIC 11.9 %, borderline.
- 5y EPS growth 32.7 %, passes.
- Gross margin 82.3 %, passes.
- FCF / Net Income 179.8 %, passes.
- Net debt / EBITDA 2.3×, passes, near the threshold.
- P/E vs own 10y history 10.4×, passes.
Against its peers (reference peers) — Tenet Healthcare Corporation: P/E 10.3×; EV/EBITDA 6.5×; ROIC 11.9 %; $21.6B. Universal Health Services, Inc. (P/E 7.2×; EV/EBITDA 5.4×; ROIC 10.4 %; $8.9B), Concentra Group Holdings Parent, Inc. (P/E 26.4×; EV/EBITDA 15.4×; ROIC 10.5 %; $5.2B), HCA Healthcare, Inc. (P/E 15.3×; EV/EBITDA 9.4×; ROIC 18.5 %; $100B).
Profitability
| Return on Equity | 50.63% |
| Return on Invested Capital | 11.91% |
| Return on Assets | 7.31% |
| Gross Margin | 26.87% |
| Operating Margin | 16.80% |
| Net Margin | 10.27% |
Financial Health
| Debt / Equity | 2.84 |
| Current Ratio | 1.41 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 1.96 |
Price Performance
| 1 month | +4.23% |
| 3 months | +5.39% |
| Year-to-date | +35.11% |
| 1 year | +28.38% |
| 3 years | +404.23% |
| 5 years | +274.69% |
| 10 years | +1262.25% |
Dividend History
| Date | Amount |
|---|---|
| 2000-03-13 | $0.0267 |
| 1993-08-16 | $0.3200 |
| 1993-05-17 | $0.3200 |
| 1993-02-12 | $0.3200 |
| 1992-11-06 | $0.3200 |
| 1992-08-10 | $0.3200 |
| 1992-05-11 | $0.3067 |
| 1992-02-10 | $0.3067 |
| 1991-11-08 | $0.3067 |
| 1991-08-12 | $0.3067 |
Amounts adjusted for stock splits.
Related companies: SGRY · HCA · UHS · CON
Explore sector: Healthcare · Medical - Care Facilities
More sections of THC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks